Drug intelligence / Profile preview

adenovirus neutralizing antibody

Development stage
Unknown
Lead developer
Guangzhou Women and Children’s Medical Center
Modality
Recombinant Proteins and Enzymes, Antibody-Based Therapeutics
Administration
Intravenous
01

Overview

Adenovirus neutralizing antibody refers to a therapeutic approach utilizing antibodies that bind to and neutralize human adenovirus (HAdV) to prevent viral entry into host cells. In clinical development, particularly by the Guangzhou Women and Children's Medical Center, this specifically refers to the use of **high-titer adenovirus neutralizing antibody plasma**. This plasma-derived biologic is collected from donors with high concentrations of specific neutralizing antibodies and administered via intravenous transfusion to provide passive immunity. The primary indication is severe adenovirus pneumonia in children, where the therapy aims to facilitate viral clearance and reduce in-hospital mortality. The efficacy of this approach is being evaluated in randomized controlled trials comparing high-titer plasma against standard plasma or supportive care.

Other names
adenovirus neutralizing antibody plasmahigh-titer adenovirus neutralizing antibody plasmaadenovirus convalescent plasma
02

Targets

Human adenovirus fiber knobHexon (Human adenovirus hexon protein)Adenovirus penton base protein

Beyond the preview

Go deeper on adenovirus neutralizing antibody.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on adenovirus neutralizing antibody.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call